The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
October 12, 2026
View Complete Issue         Table of Contents 2019 
Lunsotogene Parvec (Otarmeni) for Hearing Loss (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lunsotogene Parvec (Otarmeni) for Hearing Loss (online only)
October 12, 2026 (Issue: 1765)
Lunsotogene parvec (Otarmeni – Regeneron), an adeno-associated viral vector-based gene therapy, has received accelerated approval from the FDA for treatment of severe-to-profound or profound sensorineural hearing loss (any frequency >90 decibels...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lunsotogene Parvec (Otarmeni) for Hearing Loss (online only)
Article code: 1765d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.